Bacitracin
Bacitracin, Bacitracin / / Neomycin / Polymyxin B, Bacitracin / Neomycin / Polymyxin B, Bacitracin / Polymyxin B, Lumi-sporyn, Mycitracin (bacitracin) is a protein pharmaceutical. Bacitracin was first approved as Bacitracin on 1982-01-01. It is used to treat bacterial eye infections, bacterial skin diseases, empyema, pneumonia, and pseudomembranous enterocolitis amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bacitracin (discontinued: Baciguent, Bacitracin)
CombinationsBacitracin polymyxin b, Bacitracin-neomycin-polymyxin w/ hydrocortisone, Lumi-sporyn, Neomycin polymyxin b sulfates bacitracin, Neomycin polymyxin b sulfates, bacitracin hydrocortisone (discontinued: Bacitracin polymyxin b, Bacitracin-neomycin-polymyxin, Bacitracin-neomycin-polymyxin w/ hydrocortisone, Cortisporin, Lanabiotic, Mycitracin, Neo-polycin, Neomycin polymyxin b sulfates bacitracin, Neomycin polymyxin b sulfates, bacitracin hydrocortisone, Polysporin)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bacitracin zinc
+
Polymyxin b sulfate
Bacitracin zinc
+
Hydrocortisone
+
Neomycin sulfate
+
Polymyxin b sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| CORTISPORIN | Casper Pharma | N-050416 DISCN | 1982-01-01 | 1 products, RLD |
| CORTISPORIN | Monarch Pharmaceuticals | N-050168 DISCN | 1984-05-04 | 1 products, RLD |
Hide discontinued
Bacitracin
+
Polymyxin b sulfate
Bacitracin zinc
+
Neomycin sulfate
+
Polymyxin b sulfate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| LUMI-SPORYN | Casper Pharma | N-050417 RX | 1982-01-01 | 1 products, RLD |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 0.9g triple antibiotic | OTC monograph final | 2022-03-24 |
| 10 person ansi | OTC monograph final | 2010-06-07 |
| 25 person ansi | OTC monograph final | 2010-06-07 |
| 4314 first aid kit 4315 first aid kit | unapproved drug other | 2019-05-10 |
| 50 person ansi | OTC monograph final | 2010-06-07 |
| acme first aid contains 404 pieces | OTC monograph final | 2010-06-07 |
| acme small cuts and burns | OTC monograph final | 2010-06-14 |
| advanced first aid bacitracin | OTC monograph final | 2016-10-18 |
| adventure first aid .5 tin | OTC monograph not final | 2017-03-16 |
| adventure medical kits 1-2 person first aid | OTC monograph not final | 2011-01-11 |
Show 339 more
Indications
FDA
EMA
Show 35 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D06: Antibiotics and chemotherapeutics for dermatological use
— D06A: Antibiotics for topical use
— D06AX: Other antibiotics for topical use in atc
— D06AX05: Bacitracin
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01X: Other antibacterials in atc
— J01XX: Other antibacterials in atc
— J01XX10: Bacitracin
R: Respiratory system drugs
— R02: Throat preparations
— R02A: Throat preparations
— R02AB: Antibiotic throat preparations
— R02AB04: Bacitracin
HCPCS
No data
Clinical
Clinical Trials
46 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Infections | D007239 | EFO_0000544 | — | — | — | 1 | 5 | 3 | 9 |
| Burns | D002056 | — | T30.0 | 2 | 1 | 1 | 4 | 2 | 9 |
| Communicable diseases | D003141 | — | — | — | — | — | 3 | 2 | 5 |
| Cardiac arrhythmias | D001145 | EFO_0004269 | I49.9 | — | — | 1 | 2 | — | 3 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 1 | — | 1 | 1 | 3 |
| Infectious skin diseases | D012874 | — | — | — | — | — | 2 | 1 | 3 |
| Surgical wound infection | D013530 | — | — | — | — | — | 2 | 1 | 3 |
| Sinusitis | D012852 | EFO_0007486 | J32 | — | — | — | 2 | 1 | 3 |
| Paranasal sinus diseases | D010254 | — | — | — | 1 | — | 1 | 1 | 3 |
| Staphylococcal infections | D013203 | — | A49.01 | — | — | — | 1 | 1 | 2 |
Show 19 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Dermatitis | D003872 | HP_0011123 | L30.9 | — | 1 | 1 | — | 1 | 3 |
| Contact dermatitis | D003877 | — | L25 | — | 1 | 1 | — | 1 | 3 |
| Systolic heart failure | D054143 | EFO_1001207 | I50.20 | — | — | 1 | — | — | 1 |
| Sick sinus syndrome | D012804 | EFO_0004275 | I49.5 | — | — | 1 | — | — | 1 |
| Syncope | D013575 | HP_0012668 | G90.01 | — | — | 1 | — | — | 1 |
| Heart block | D006327 | — | I45.89 | — | — | 1 | — | — | 1 |
| Edema | D004487 | HP_0000969 | R60.9 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Allergic contact dermatitis | D017449 | — | L23 | — | 1 | — | — | 1 | 2 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Osteomyelitis | D010019 | EFO_0003102 | M86 | 1 | — | — | — | — | 1 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 1 | — | — | — | — | 1 |
| Mammaplasty | D016462 | — | — | 1 | — | — | — | — | 1 |
| Prosthesis-related infections | D016459 | EFO_1001406 | — | 1 | — | — | — | — | 1 |
| Covid-19 | D000086382 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 1 | 1 |
| Herpes simplex | D006561 | — | B00 | — | — | — | — | 1 | 1 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
| Finger injuries | D005383 | — | — | — | — | — | — | 1 | 1 |
| Traumatic amputation | D000673 | — | — | — | — | — | — | 1 | 1 |
| Bites and stings | D001733 | — | — | — | — | — | — | 1 | 1 |
| Sepsis | D018805 | HP_0100806 | A41.9 | — | — | — | — | 1 | 1 |
| Skin diseases | D012871 | — | L00-L99 | — | — | — | — | 1 | 1 |
| Hernia | D006547 | HP_0100790 | K40-K46 | — | — | — | — | 1 | 1 |
| Otitis media | D010033 | EFO_0004992 | H66.9 | — | — | — | — | 1 | 1 |
Show 4 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bacitracin |
| INN | bacitracin |
| Description | Bacitracin is a mixture of related cyclic peptides produced by organisms of the licheniformis group of Bacillus subtilis var Tracy, first isolated in 1945. These peptides disrupt Gram-positive bacteria by interfering with cell wall and peptidoglycan synthesis.
|
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](N)C1=N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(=O)O)C(=O)N[C@H](C(=O)N[C@H]2CCCCNC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](CC(=O)O)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@@H](Cc3ccccc3)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](CCCN)NC2=O)[C@@H](C)CC)CS1 |
Identifiers
| PDB | — |
| CAS-ID | 22601-59-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1200558 |
| ChEBI ID | 35862 |
| PubChem CID | 439542 |
| DrugBank | DB00626 |
| UNII ID | 58H6RWO52I (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bacitracin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Neomycin
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Polymyxin b
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Bacitracin
+
Polymyxin b
+
Pramoxine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 15,484 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,716 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use